Table 2 Applications of GBNs in gene-based therapy
From: Graphene-based nanomaterials for breast cancer treatment: promising therapeutic strategies
References | Type of GBN | Targeting ligands | Modification | Gene | Properties | Cell line | Results |
|---|---|---|---|---|---|---|---|
[151] | GO | _ | PEI | siRNA | _ | MDA-MB-231 | Suppressed the gene expression and metastatic potential of breast cancer cells |
[152] | GO | _ | CPPs, PL-PEG | siRNA | _ | MCF-7 | Showed significant cell death |
[153] | GO | P-L-Arg | Au | miRNA-101 | Gene release was improved by NIR thermal therapy | MCF-7, MDA | Reduced the viability of MCF-7 cell lines |
[154] | GO | P-L-Arg | PEG | miR-101 | Higher miRNA payload, selective transfection | MCF-7, MDA-MB-231 | Autophagy was downregulated, and the apoptosis cascade was activated |
[155] | GO | _ | Hap, ganciclovir | HSV-TK | Tumor-specific promoters | MCF-7, MDA-MB-231, MCF-10A | Induced the apoptosis of breast cancer cells and inhibited their growth |
[156] | GO | _ | PEG-diamine, R8 | siRNA and pDNA | Superior internalization efficacy of 85% | MCF-7, MDA-MB-231 | Protected siRNA and pDNA against enzyme degradation |
[139] | GO | _ | _ | MDR1 beacon, ETS1 beacon | _ | MCF-7/Adr | Reversed MDR |
[150] | GO | _ | PAMAM, PEG | siRNA | pH-triggered release of siRNA | MDA-MB-231 | Effectively silenced genes with high transfection efficiency |